NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural ...
For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...
When a biopharma company known for its expertise in a specific domain turns to a collaborator to expand its capabilities in ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
B Capital, a global multi-stage investment firm, today announced that it has been selected as a registered venture capital firm under the Government of Japan’s Agency for Medical Research and ...
In February, a small biotech company reached a breakthrough with the FDA, agreeing to a clinical trial plan. The problem: The ...
The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...
StockStory.org on MSN
Reflecting on drug development inputs & services stocks’ Q4 earnings: IQVIA (NYSE:IQV)
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug ...
US drugmaker Eli Lilly has signed a $2bn deal with a Hong Kong-listed company that uses AI for drug discovery, highlighting ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or the 'Company', 6990.HK) today announced that following an application to The Stock Exchange of Hong Kong Limited (the 'Stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results